Literature DB >> 2108057

Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval.

M I Cedars1, E Surey, F Hamilton, P Lapolt, D R Meldrum.   

Abstract

Levels of immunoreactive luteinizing hormone (LH), bioactive LH, and testosterone (T) were determined in 52 women receiving human menopausal gonadotropins (hMG). In 26 women receiving leuprolide acetate (LA) preceding hMG, there was a significant suppression of immunoreactive LH and bioactive LH. The characteristic increase in serum levels of bioactive LH and T were absent. Follicular fluid estradiol and T concentrations, and serum progesterone were not different. The lower circulating levels of T may reflect reduced LH-stimulated androgen accumulation in smaller nonaspirated follicles and may account for the enhanced follicle recruitment observed during LA. The lack of premature luteinization despite marked rises of bioactive LH in the absence of LA is consistent with normal events during the menstrual cycle and was due to the early termination of hMG stimulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108057     DOI: 10.1016/s0015-0282(16)53454-2

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

1.  The Ideal Stimulation Protocol: Is There One?

Authors:  Gautam N Allahbadia
Journal:  J Obstet Gynaecol India       Date:  2015-07-01

2.  Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.

Authors:  T J Gelety; E S Surrey
Journal:  J Assist Reprod Genet       Date:  1997-10       Impact factor: 3.412

3.  A modest increase in serum progesterone levels on the day of human chorionic gonadotropin (hCG) administration may influence pregnancy rate and pregnancy loss in in vitro fertilization-embryo transfer (IVF-ET) patients.

Authors:  M Dirnfeld; S Goldman; Y Gonen; M Koifman; A Lissak; H Abramovici
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

Review 4.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

5.  Elevated serum progesterone values at the time of ovulation induction in luteal leuprolide acetate-down-regulated GIFT cycles are associated with decreased clinical pregnancy rates.

Authors:  G W Randall; P A Gantt; D Gantt; M J Kirk; N Romines
Journal:  J Assist Reprod Genet       Date:  1996-07       Impact factor: 3.412

6.  A randomized prospective study on the effect of short and long buserelin treatment in women with repeated unsuccessful in vitro fertilization (IVF) cycles due to inadequate ovarian response.

Authors:  M Dirnfeld; Y Gonen; A Lissak; S Goldman; M Koifman; Y Sorokin; H Abramovici
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-12

7.  The effects of gonadotropin-releasing hormone agonist on androstenedione production and follicular development during controlled ovarian hyperstimulation.

Authors:  K Akaboshi; T Oda; J Yoshida; S Kohriyama; T Miyazaki; Y Yoshimura
Journal:  J Assist Reprod Genet       Date:  1998-09       Impact factor: 3.412

8.  Low dose gonadotropin-releasing hormone agonist treatments with early discontinuation for controlled ovarian hyperstimulation in an in vitro fertilization program.

Authors:  Su-Long Lee; Jinu-Hwang Su; Katsuo Ikuta; Kaoru Suzumori
Journal:  Reprod Med Biol       Date:  2003-03-25

Review 9.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.